Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is a prevalent global
infectious disease and a leading cause of mortality worldwide. Currently, the only available …

Breakthrough findings in the clinical and preclinical development of tuberculosis (TB)
vaccines have galvanized the field and suggest, for the first time since the development of …

The clinical use of antibiotics has led to the emergence of multidrug-resistant (MDR)
bacteria, leading to the current antibiotic resistance crisis. To address this issue, next …

Abstract Background Bacille Calmette-Guérin (BCG) vaccination can potentially reduce the
rate of respiratory infections in vulnerable populations. This study evaluates the safety and …

Background Tuberculosis (TB) is preventable and curable but eliminating it has proven
challenging. Safe and effective TB vaccines that can rapidly reduce disease burden are …

Background Most individuals developing tuberculosis (TB) are working age adults living in
low-and middle-income countries (LMICs). The resulting disability and death impact …

Tuberculosis (TB) remains a serious public health threat around the world. An effective
vaccine is urgently required for cost-effective, long-term control of TB. However, the only …

Tuberculosis (TB) is still the leading global cause of death from an infectious bacterial agent.
Limiting tuberculosis epidemic spread is therefore an urgent global public health priority. As …

Although tuberculosis (TB) remains one of the leading causes of death from an infectious
disease worldwide, the development of vaccines more effective than bacille Calmette …

Vaccination is an excellent approach to stimulating the host immune response and reducing
human morbidity and mortality against microbial infections, such as tuberculosis (TB) …